ctDNA SNORD3F Hypermethylation is a Prognostic Indicator in EGFR-TKI-Treated Advanced Non-Small Cell Lung Cancer

被引:0
|
作者
Liu, Bin [1 ]
Zhao, Bingtian [1 ]
Yin, Yan [1 ]
Jiang, Yan [1 ]
Feng, Xue [1 ]
Wang, Lei [1 ]
Zhai, Liang [1 ]
Liu, Guangxin [1 ]
Shi, Dongsheng [1 ]
Qin, Jianwen [1 ]
机构
[1] Tianjin Chest Hosp, Dept Resp & Crit Med, Tianjin, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2024年 / 16卷
关键词
ctDNA; EGFR; DNA methylation; lung cancer; snoRNA; SNORD3F; CIRCULATING TUMOR DNA; GEFITINIB RESISTANCE; METHYLATION; MUTATIONS; NSCLC;
D O I
10.2147/CMAR.S474241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: DNA methylation plays a regulatory role in the oncogenesis and tumor progression and is valuable in the diagnosis and prognosis of cancer. While circulating tumor DNA (ctDNA) is widely used in the detection of oncogenic mutations and the guidance of treatment in advanced non-small cell lung cancer (NSCLC), studies of ctDNA methylation remains insufficient. We aim to investigate the methylation profiles of ctDNA in patients with advanced NSCLC undergoing EGFR-tyrosine kinase inhibitor (EGFRTKI) therapy and to discover novel biomarkers with predictive or prognostic value. Patients and Methods: We recruited 49 patients with EGFR-mutated advanced NSCLC undergoing EGFR-TKI as first-line treatment. Utilizing next-generation sequencing, we examined the somatic mutations and methylation signatures within the tumorassociated genomic regions of ctDNA from pre-treatment blood. Subsequently, we explored the association of these molecular features with the patients' response to therapy and their progression-free survival (PFS). Results: Genomic mutation profiling revealed no significant association of PFS or best overall response (BOR) and ctDNA status. Evaluation of ctDNA methylation showed a negative correlation between the methylation of small nucleolar RNA (snoRNA) genes and PFS (R=-0.31, P=0.043). Furthermore, high-level methylation of SNORD3F was associated with poorer PFS (mPFS 346d vs 243d, HR 0.49, 95% CI 0.24-0.93, P=0.029). Conclusion: Our study explored the prognostic value of ctDNA methylation in patients with advanced NSCLC undergoing targeted therapies and first revealed the predictive role of SNORD3F.
引用
收藏
页码:1405 / 1416
页数:12
相关论文
共 50 条
  • [31] Predictive and prognostic values of circulating tumor DNA (ctDNA) clearance in osimertinib treated advanced non-small cell lung cancer cohort
    Song, Yong
    Ma, Shenglin
    Shi, Meiqi
    Xu, Xingxiang
    Chen, Xueqin
    Wang, Yong
    Yang, Zhenhua
    Zhang, Tengfei
    Li, Min
    Li, Haiyan
    Zhang, Lu
    Mao, Xinru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Investigation of AKT3 in the resistance of non-small cell lung cancer to EGFR-TKI
    Huang, Shih-Hsiang
    Shih, Jin-Yuan
    Chen, Ching-Chow
    CANCER RESEARCH, 2019, 79 (13)
  • [33] Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment
    Kasahara, Norimitsu
    Imai, Hisao
    Naruse, Ichiro
    Tsukagoshi, Yusuke
    Kotake, Mie
    Sunaga, Noriaki
    Kaira, Kyoichi
    Maeno, Toshitaka
    Asao, Takayuki
    Hisada, Takeshi
    THORACIC CANCER, 2020, 11 (08) : 2188 - 2195
  • [34] Is MPV a Real Prognostic Indicator for Non-small Cell Lung Cancer?
    Ozyalvacli, Gulzade
    Yasar, Zehra
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (18) : 8003 - 8003
  • [35] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [36] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [37] The depth of response was associated with the progression-free survival in advanced non-small cell lung cancer patients treated with EGFR-TKI
    Liu, Yutao
    Zhang, Kai
    Li, Chengcheng
    Hu, Xingsheng
    Jiang, Jun
    Hao, Xuezhi
    Wang, Yan
    Li, Junling
    Xing, Puyuan
    Yang, Sheng
    Zhang, Xin
    Wang, Guoqiang
    Cai, Shangli
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI
    Liu, Yu-Tao
    Zhang, Kai
    Li, Cheng-Cheng
    Hu, Xing-Sheng
    Jiang, Jun
    Hao, Xue-Zhi
    Wang, Yan
    Li, Jun-Ling
    Xing, Pu-Yuan
    Yang, Sheng
    Zhang, Xin
    Wang, Guo-Qiang
    Cai, Shang-Li
    Shi, Yuan-Kai
    JOURNAL OF CANCER, 2019, 10 (21): : 5108 - 5113
  • [39] Uncommon EGFR mutations in advanced non-small cell lung cancer
    O'Kane, Grainne M.
    Bradbury, Penelope A.
    Feld, Ronald
    Leighl, Natasha B.
    Liu, Geoffrey
    Pisters, Katherine -M.
    Kamel-Reid, Suzanne
    Tsao, Ming S.
    Shepherd, Frances A.
    LUNG CANCER, 2017, 109 : 137 - 144
  • [40] Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)
    He, Jingyi
    Huang, Zhengrong
    Han, Linzhi
    Gong, Yan
    Xie, Conghua
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2021, 59 (05)